New targets in inflammatory bowel disease therapy: 2021

Curr Opin Gastroenterol. 2021 Jul 1;37(4):357-363. doi: 10.1097/MOG.0000000000000740.

Nathaniel A Cohen 1, David T Rubin


Author information

  • 1The University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, USA.


Purpose of review: In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD).

Recent findings: Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies.

Summary: The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.



© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.